Hallucinogens: an update.
Current Psychiatry Reports October 1, 2003 DOI: 10.1007/s11920-003-0067-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Psychoactive substances: entheogens Mind-altering compounds Novel compounds Nonaddictive compounds Psychotropic substances Recovery Anti-addictive potential Therapeutic applications Dependency solutions Entheogenic rituals Sacred ceremonies Ritual use Harm reduction Nuanced understanding Re-evaluation Positive impact Beneficial uses |
| Citations | 42 |
| Key findings | Hallucinogens may have anti-addictive applications and potential legitimate societal benefits, warranting further methodologically sound research. |
Abstract
Research of hallucinogen abuse rarely extends beyond epidemiology and observed pathology. Even less research has been completed on the special circumstances surrounding the religious use of hallucinogens or on potential therapeutic applications. Rather than offer another basic review on the well-known hazards of illicit hallucinogen use, this paper provides an overview and practice recommendations on compounds the clinician may be less familiar with, such as the botanical plant Salvia divinorum, the drug 3,4-methylenedioxymethamphetamine ("ecstasy") and synthetic hallucinogen analogs. The often-warned, but rarely occurring, hazard of hallucinogen persisting perception disorder ("flashbacks") is also reviewed with treatment recommendations provided. The current status of clinical research with the hallucinogens is presented, with case vignettes suggesting hallucinogens may have anti-addictive applications. The special circumstances surrounding the religious, nondrug use of hallucinogens as sacred sacraments in the US and elsewhere are also presented. It is hoped that the reader will gain a more nuanced understanding of how these physiologically nonaddictive drugs may offer legitimate benefits in modern society. By appreciating that such benefits may one day be borne out by careful, methodologically sound research, clinicians should be better armed in raising the topic of hallucinogen use and abuse with their patients.
Citations in the library
Cited by 23
- Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Journal of Psychopharmacology February 9, 2015
- Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment Progress in Neuro-Psychopharmacology and Biological Psychiatry June 10, 2012
- Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews March 1, 2013
- A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharmacy world & science : PWS April 1, 2004
- In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users Archives of General Psychiatry June 6, 2011
and 18 more in the library
Cites 23
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
- ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE The Journal of Nervous and Mental Disease October 1, 1984
- Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Journal of Psychoactive Drugs June 1, 1997
- Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment December 1, 2002
and 18 more in the library